UroGen Pharma (URGN) Resumen de Acciones
UroGen Pharma Ltd., empresa de biotecnología, se dedica al desarrollo y comercialización de soluciones para el cáncer urotelial y otros cánceres especializados. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 0/6 |
| Dividendos | 0/6 |
URGN Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de UroGen Pharma Ltd.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$38.02 |
| Máximo en las últimas 52 semanas | US$39.59 |
| Mínimo de 52 semanas | US$13.26 |
| Beta | 1.57 |
| Cambio en 1 mes | 41.60% |
| Variación en 3 meses | 110.87% |
| Cambio de 1 año | 181.84% |
| Variación en 3 años | 241.91% |
| Variación en 5 años | 155.68% |
| Variación desde la OPV | 171.96% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 18
URGN: Patent Overhang And Execution Risks Will Likely Cap Stock Price Upside
Analysts have trimmed their average price target for UroGen Pharma to about $20.55, a slight adjustment they link to updated assumptions around revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research around UroGen Pharma highlights a mix of optimism on the product story and tighter scrutiny on what that implies for valuation, especially relative to updated assumptions on revenue, margins and future P/E multiples.
Actualización de narrativa • Jun 04
URGN: Future Bladder Cancer Trial Milestones May Reframe Long Term Upside Potential
Analysts have reset the 12 month price target for UroGen Pharma to $45.00, reflecting updated assumptions around revenue growth, profit margins, and a slightly higher discount rate, while citing supportive recent research coverage and target increases from multiple firms. Analyst Commentary Recent research coverage on UroGen Pharma has leaned positive, with several bullish analysts updating their views and models following new information on the company and its pipeline.Actualización de narrativa • May 21
URGN: Future Regulatory And Funding Setbacks Will Likely Restrain Upside Potential
Narrative Update on UroGen Pharma The updated analyst price target for UroGen Pharma has shifted from about $19.68 to roughly $20.86 as analysts incorporate recent initiations and target increases, including the $5 and $6 target hikes and renewed Buy views, into their valuation work. Analyst Commentary Recent research on UroGen Pharma has leaned constructive, with several firms initiating or reaffirming Buy views and lifting their price targets.Recent updates
Actualización de narrativa • Jun 18
URGN: Patent Overhang And Execution Risks Will Likely Cap Stock Price Upside
Analysts have trimmed their average price target for UroGen Pharma to about $20.55, a slight adjustment they link to updated assumptions around revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research around UroGen Pharma highlights a mix of optimism on the product story and tighter scrutiny on what that implies for valuation, especially relative to updated assumptions on revenue, margins and future P/E multiples.Actualización de narrativa • Jun 04
URGN: Future Bladder Cancer Trial Milestones May Reframe Long Term Upside Potential
Analysts have reset the 12 month price target for UroGen Pharma to $45.00, reflecting updated assumptions around revenue growth, profit margins, and a slightly higher discount rate, while citing supportive recent research coverage and target increases from multiple firms. Analyst Commentary Recent research coverage on UroGen Pharma has leaned positive, with several bullish analysts updating their views and models following new information on the company and its pipeline.Actualización de narrativa • May 21
URGN: Future Regulatory And Funding Setbacks Will Likely Restrain Upside Potential
Narrative Update on UroGen Pharma The updated analyst price target for UroGen Pharma has shifted from about $19.68 to roughly $20.86 as analysts incorporate recent initiations and target increases, including the $5 and $6 target hikes and renewed Buy views, into their valuation work. Analyst Commentary Recent research on UroGen Pharma has leaned constructive, with several firms initiating or reaffirming Buy views and lifting their price targets.Seeking Alpha • May 07
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
Summary UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J-code assignment, validating the trajectory toward profitability by 2027. URGN's path to profitability is underpinned by >91% gross margins, disciplined expense control, and a realistic break-even threshold of $305M annual revenue. Risks include execution on Zusduri adoption, debt burden, and long-term generic threats, but current sales momentum and operating leverage support the bullish thesis. Read the full article on Seeking AlphaActualización de narrativa • May 03
URGN: Future Regulatory And Cost Setbacks Will Likely Restrain Upside Potential
Analysts have raised their price target on UroGen Pharma from $16.57 to $19.68 as updated assumptions for revenue growth, profit margins and a lower future P/E multiple align with a recently initiated bullish view on the stock. Analyst Commentary Recent research commentary on UroGen Pharma reflects a bullish initiation that aligns with the higher price target.
Actualización de narrativa • Apr 18
URGN: Future Profit Margins Will Improve Through LG UTUC Trial Momentum
Analysts have nudged their price target for UroGen Pharma higher to $36.11 from $35.63, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E following recent bullish Street research coverage. Analyst Commentary Recent Street research on UroGen Pharma has leaned constructive, which feeds into the modest uptick in the blended price target to $36.11.Actualización de narrativa • Apr 03
URGN: Future Profit Margins Will Improve Through New J Code Reimbursement
Analysts have modestly fine-tuned their price target framework for UroGen Pharma, keeping fair value around $35.63. Small adjustments to the discount rate, revenue growth, profit margin, and forward P/E reflect updated assumptions rather than a major change in outlook.Actualización de narrativa • Mar 20
URGN: Future Profit Margins Will Benefit From New J Code And Loan Refinancing
Analysts kept their fair value estimate for UroGen Pharma steady at $35.63 while making only minimal adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E. These changes reflect updated views on operating costs and financing conditions, similar to those that recently led to modest target reductions in other healthcare names.Actualización de narrativa • Mar 05
URGN: Future Profit Margins Will Benefit From New J Code Reimbursement
Analysts now place UroGen Pharma's fair value at about $35.63, compared with the prior $35.25. This reflects updated assumptions around a slightly higher discount rate, modestly adjusted revenue growth and profit margin expectations, and a higher future P/E estimate.Artículo de análisis • Dec 05
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders have had their patience rewarded with a 26% share price jump in the...Actualización de narrativa • Nov 26
URGN: Future Profit Margins Will Benefit From Recent Regulatory Milestones
Analysts have raised their price target for UroGen Pharma from $33.75 to $35.25. They cite expectations of stronger revenue growth and improved profit margins as key drivers for the increase.Artículo de análisis • Oct 06
UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues
It's not a stretch to say that UroGen Pharma Ltd.'s ( NASDAQ:URGN ) price-to-sales (or "P/S") ratio of 8.5x right now...Actualización de narrativa • Sep 09
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
Driven by an improved net profit margin and a modest reduction in future P/E, analysts have raised UroGen Pharma’s consensus price target from $32.00 to $33.75. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only approved therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.Actualización de narrativa • Aug 15
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
As there is no change in the key metrics—consensus price target ($31.43), discount rate (6.85%), and future P/E (15.67x)—analyst valuation for UroGen Pharma remains steady, reflecting an unchanged fair value. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.Artículo de análisis • Aug 10
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
NasdaqGM:URGN 1 Year Share Price vs Fair Value Explore UroGen Pharma's Fair Values from the Community and select yours...Artículo de análisis • Jul 07
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders would be excited to see that the share price has had a great month...Artículo de análisis • May 17
Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop
The UroGen Pharma Ltd. ( NASDAQ:URGN ) share price has fared very poorly over the last month, falling by a substantial...Artículo de análisis • May 15
Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63
It's shaping up to be a tough period for UroGen Pharma Ltd. ( NASDAQ:URGN ), which a week ago released some...Nueva narrativa • May 07
UGN-102 Approval Will Broaden Bladder Cancer Treatment Options
Anticipated approval of UGN-102 could significantly expand UroGen Pharma's market, boosting revenues with its compelling response rates and potential pricing power.Artículo de análisis • Feb 12
Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 4.8x UroGen Pharma Ltd. ( NASDAQ:URGN ) is definitely a...Seeking Alpha • Jan 31
UroGen: Upcoming PDUFA, Some Concerns Remain
Summary UroGen's Jelmyto, a gel-based mitomycin product for LG-UTUC, achieved $25.2mn in Q3 2024, marking a 20% YoY increase. Lead candidate UGN-102 shows promise in treating low-grade intermediate risk NMIBC, with significant clinical trial success and a PDUFA date set for June 13, 2025. Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva. Despite promising data and market potential, UroGen's low market cap suggests caution; a pilot investment is recommended with awareness of associated risks. Read the full article on Seeking AlphaArtículo de análisis • Nov 18
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Aug 28
UroGen Pharma: There Is Some Potential Here
Summary UroGen Pharma Ltd. focuses on urothelial and specialty cancers, with Jelmyto approved for LG-UTUC and promising pipeline candidates like UGN-102 for bladder cancer. UGN-102 should garner FDA approval in the first half of 2025 and has a much bigger potential market than Jelmyto. UroGen is also advancing some next-generation candidates within its pipeline and has adequate near-term funding in place. An analysis around UroGen Pharma follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 17
UroGen: Q3 NDA Opens Hefty Revenue Opportunity
Summary ENVISION DOR data released in Q2, 2024 showed an unprecedented 82.3% Duration of Response for UGN-102. Following such positive data, it expects to make an FDA submission late in Q3, 2024, with potential for priority review. UroGen Pharma's blockbuster drug potential, liquidity, and modest market cap make it a strong buy. Read the full article on Seeking AlphaArtículo de análisis • Jun 14
UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders would be excited to see that the share price has had a great month...Artículo de análisis • Apr 09
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
UroGen Pharma Ltd. ( NASDAQ:URGN ) shares have had a horrible month, losing 27% after a relatively good period...Seeking Alpha • Mar 18
UroGen: All Eyes On UGN-102
Summary JELMYTO revenues are growing but not by enough to support UroGen's operations. Guided financials show ongoing losses with adequate liquidity for its near-term UGN-102 development. If all goes as hoped, UroGen will launch UGN-102 in Q1 2025. Read the full article on Seeking AlphaArtículo de análisis • Mar 17
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
It's been a sad week for UroGen Pharma Ltd. ( NASDAQ:URGN ), who've watched their investment drop 20% to US$14.46 in...Artículo de análisis • Jan 18
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
UroGen Pharma Ltd.'s ( NASDAQ:URGN ) price-to-sales (or "P/S") ratio of 6.2x might make it look like a strong buy right...Rentabilidad de los accionistas
| URGN | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 5.4% | 4.1% | 1.6% |
| 1Y | 181.8% | 41.1% | 18.6% |
Rentabilidad vs. Industria: URGN superó a la industria US Biotechs, que obtuvo un rendimiento del 41.1% el año pasado.
Rentabilidad vs. Mercado: URGN superó al mercado US, que obtuvo un rendimiento del 18.6% el año pasado.
Volatilidad de los precios
| URGN volatility | |
|---|---|
| URGN Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: URGN no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de URGN (9%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2004 | 298 | Liz Barrett | www.urogen.com |
UroGen Pharma Ltd., empresa de biotecnología, se dedica al desarrollo y comercialización de soluciones para cánceres uroteliales y especializados. Ofrece RTGel, una novedosa tecnología patentada de hidrogeles poliméricos biocompatibles de gelificación térmica inversa; Mitomycin, un fármaco genérico utilizado fuera de indicación como quimioterapia adyuvante para el tratamiento del cáncer de vejiga de bajo grado después de la resección transuretral del tumor de vejiga; Zusduri, una formulación de mitomicina de liberación sostenida para el tratamiento del cáncer de vejiga no músculo-invasivo (CCNMI); y Jelmyto para soluciones pielocaliciales. Los principales productos candidatos de la empresa son el UGN-103, en fase 3 de ensayo clínico para solución intravesical, y el UGN-104, en fase 3 de ensayo clínico para solución pielocalicial, diseñados para el tratamiento de varias formas de cáncer urotelial no músculo-invasivo, como el cáncer urotelial de vías altas de bajo grado y el NMIBC de bajo grado y riesgo intermedio.
Resumen de fundamentos de UroGen Pharma Ltd.
| Estadísticas fundamentales de URGN | |
|---|---|
| Capitalización bursátil | US$1.85b |
| Beneficios(TTM) | -US$133.22m |
| Ingresos (TTM) | US$140.49m |
13.2x
Ratio precio-ventas (PS)-13.9x
Ratio precio-beneficio (PE)¿Está URGN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de URGN | |
|---|---|
| Ingresos | US$140.49m |
| Coste de los ingresos | US$14.26m |
| Beneficio bruto | US$126.24m |
| Otros gastos | US$259.46m |
| Beneficios | -US$133.22m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.73 |
| Margen bruto | 89.85% |
| Margen de beneficio neto | -94.83% |
| Ratio deuda/patrimonio | -152.5% |
¿Cómo se ha desempeñado URGN a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/06 09:05 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
UroGen Pharma Ltd. está cubierta por 22 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Anita Dushyanth | Berenberg |
| Jason Kolbert | D. Boral Capital LLC. |
| Paul Choi | Goldman Sachs |